Prof. Zefei Jiang 江泽飞
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical research in breast cancer, including endocrine therapy for premenopausal patients, chemotherapy for hormone-independent breast cancer, and targeted therapy strategies.
Dr. Jiang is a Chief Physician, Professor, and Director of the Third Oncology Department (Breast Medical Oncology) at Chinese PLA General Hospital. Holding a medical doctorate, Dr. Jiang has 20 years of experience in oncology clinical practice and basic research. After training under Chief Physician Santai Song, Dr. Jiang conducted guest research at City of Hope National Medical Center in the US from 1999 to 2001.
Professional roles
- Standing Committee Member, Chinese Society of Clinical Oncology (CSCO)
- New Drug Review Expert, State Food and Drug Administration (SFDA)
Name order: in Chinese the family name comes first (Jiang Zefei). Papers usually list the name as Zefei Jiang or Jiang Z.
Selected publications
93 papers on PubMed matched by name and affiliation; 49 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Breast Cancer Res, 2026 (senior author): Sacituzumab govitecan plus toripalimab compared with toripalimab plus nab-paclitaxel for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer: protocol of a multicenter, open-label, randomized phase II trial. PubMed 42991455
- Cancer Med, 2026 (senior author): Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study. PubMed 42162577
- Cancer Biol Med, 2026 (senior author): Artificial intelligence in breast cancer: applications and advancements. PubMed 41968983
- Cancer Biol Med, 2026 (first author): Artificial intelligence empowering precision diagnosis and treatment of breast cancer: advancing global clinical practice with regional insights. PubMed 41968980
- Cancer Biol Med, 2026 (senior author): Protocol and statistical designs in classic clinical research-toripalimab series trial analysis. PubMed 41968978
- EClinicalMedicine, 2026 (senior author): Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study. PubMed 41502924
- Signal Transduct Target Ther, 2025 (senior author): Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. PubMed 41413016
- Eur J Cancer, 2025 (senior author): Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial. PubMed 40992225
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion